Eicosanoid pathway in colorectal cancer: Recent updates

World Journal of Gastroenterology

Volumn 21, Issue 41, 2015, Pages 11748-11766

  Tuncer, Sinem ^a   Banerjee, Sreeparna ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Colorectal cancer; Cyclooxygenase; Eicosanoids; Inflammation; Lipoxygenase

Indexed keywords

CYCLOOXYGENASE 2; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYUNSATURATED FATTY ACID; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; UNSATURATED FATTY ACID;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; HUMAN; INFLAMMATION; METASTASIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; EICOSANOIDS; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84947250881     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i41.11748     Document Type: Article

References (207)

1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899 [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025]
2. Gajewski TF, W oo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013; 25: 268-276 [PMID: 23579075 DOI: 10.1016/j.coi.2013.02.009]
3. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 2008; 27: 31-40 [PMID: 18087678 DOI: 10.1007/s10555-007-9108-5]
4. Ullman TA,Itzkowitz SH. Intestinal inflammation and cancer Gastroenterology 2011 140 1807-1816 PMID: 21530747 DOI: 10.1053/j.gastro.2011.01.057]
5. Yarur AJ, Strobel SG, Deshpande AR, Abreu MT. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2011; 7: 652-659 [PMID: 22298958]
6. Oshima M, Taketo MM. COX selectivity and animal models for colon cancer. Curr Pharm Des 2002; 8: 1021-1034 [PMID: 11945149 DOI: 10.2174/1381612023394953]
7. Atreya I, Neurath MF. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 2008; 8: 561-572 [PMID: 18402523 DOI: 10.158 6/14737140.8.4.561
8. Sung SY, Hsieh CL, Wu D, Chung LW, Johnstone PA. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 2007; 31: 36-100 [PMID: 17362788 DOI: 10.1016/j.currproblcancer.2006.12.002]
9. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148 [PMID: 15308095 DOI: 10.1016/j.immuni.2004.07.017]
10. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008; 99: 1501-1506 [PMID: 18754859 DOI: 10.1111/j.1349-7006.2008.00853.x]
11. Greene ER, Huang S, Serhan CN, Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat 2011; 96: 27-36 [PMID: 21864702 DOI: 10.1016/j.prostagl andins.2011.08.004]
12. Mariani F, Sena P, Roncucci L. Inflammatory pathways in the early steps of co lorectal cancer development. World J Gastroenterol 2014; 20: 9716-9731 [PMID: 25110410 DOI: 10.3748/wjg.v20. i29.9716]
13. Kuhn H, Banthiya S, van Leyen K. Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta 2015; 1851: 308-330 [PMID: 25316652 DOI: 10.1016/j.bbalip.2014.10.002]
14. Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta 2015; 1851: 469-484 [PMID: 25149823 DOI: 10.1016/j.bbalip.2014.08.010]
15. Kew S, Mesa MD, Tricon S, Buckley R, Minihane AM, Yaqoob P. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. Am J Cl in Nutr 2004; 79: 674-681 [PMID: 15051614 DOI: 10.1016/j.atherosclerosis.2004.04.004]
16. Rees D, Miles EA, Banerjee T, Wells SJ, Roynette CE, Wahle KW, Calder PC. Dose-rela ted effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 2006; 83: 331-342 [PMID: 16469992]
17. Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, Yuan C, Warnock M, Schmaier AH, Yokoyama C, Smyth EM, Wilson SJ, FitzGerald GA, Garavito RM, Sui de X, Regan JW, Smith WL. Enzymes and receptors of prostaglandin pat h ways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 2007; 282: 22254-22266 [PMID: 17519235 DOI: 10.1074/jbc.M703169200]
18. Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev 2011; 30: 507-523 [PMID: 22015691 DOI: 10.1007/s10555-011-9311-2]
19. Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut 2012; 61: 135-149 [PMID: 21490374 DOI: 10.1136/gut.2010.233718]
20. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-193 [PMID: 20168319 DOI: 10.1038/nrc2809]
21. Sheng H, Shao J, Williams CS, Pereira MA, Taketo MM, Oshima M, Reynolds AB, Washington MK, DuBois RN, Beauchamp RD. Nuclear translocation of beta-catenin in hereditary and carcinogeninduced intestinal adenomas. Carcinogenesis 1998; 19: 543-54 9 [PMID: 9600336 DOI: 10.1093/carcin/19.4.543]
22. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 2005; 69 Suppl 1: 28-32 [PMID: 16210874 DOI: 10.1159/000086629]
23. Jiang J, Dingledine R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther 20 13; 344: 360-367 [PMID: 23192657 DOI: 10.1124/jpet.112.200444]
24. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-658 [PMID: 19671906 DOI: 10.1001/jama.2009.1112]
25. Wang W, Zhu J, Lyu F, Panigrahy D, Ferrara KW, Hammock B, Zhang G. ?-3 polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer. Prostaglandins Other Lipid Mediat 2014; 113-115: 13-20 [PMID: 25019221 DOI: 10.1016/j.prostaglandins.2014.07.002]
26. Tanaka S, Tatsuguchi A, Futagami S, Gudis K, Wada K, Seo T, Mitsui K, Yonezawa M, Nagata K, Fujimori S, Tsukui T, Kishida T, Sakamoto C. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut 2 006; 55: 54-61 [PMID: 16085694 DOI: 10.1136/gut.2004.059824]
27. Kaliski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001; 97: 3466-3469 [PMID: 11369638 DOI: 10.1182/blood.V97.11.3466]
28. Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D. Prostaglandin E2 induces IL-23 production in bone marrowderived dendritic cells. FASEB J 2004; 18: 1318-1320 [PMID: 15180965 DOI: 10.10 96/fj.03-1367fje]
29. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through th e IL-23-& gt; IL-17 axis. J Immunol 2007; 178: 8138-8147 [PMID: 17548652 DOI: 10.4049/jimmunol.178.12.8138]
30. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009; 15: 633-640 [PMID: 19465928 DOI: 10.1038/nm.1968]
31. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjørnbeth BA, Taskén K. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunot her 2008; 57: 813-821 [PMID: 17962941 DOI: 10.1007/s00262-007-0417-x]
32. Göbel C, Breitenbuecher F, Kalkavan H, Hähnel PS, Kasper S, Hoffarth S, Merches K, Schild H, Lang KS, S chuler M. Functional expression cloning identifies COX-2 as a suppressor of antigenspecific cancer immunity. Cell Death Dis 2014; 5: e1568 [PMID: 25501829 DOI: 10.1038/cddis.2014.531]
33. Wang Q, Takei Y, Kobayashi O, Osada T, Watanabe S. Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. J Clin Biochem Nutr 2009; 45: 163-170 [PMID: 19794924 DOI: 10.3164/jcbn.09-21]
34. Montrose DC, Nakanishi M, Murphy RC, Zarini S, McAleer JP, Vella AT, Rosenberg DW. The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat 2014; 116-117: 26-36 [PMID: 25460828 DOI: 10.1016/j.prostaglandins.2014.10.002]
35. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 2008; 68: 3251-3259 [PMID: 18451151 DOI: 10.1158/0008-5472. CAN-07-6100]
36. Dey I, Lejeune M, Chadee K. Prostaglan din E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol 2006; 149: 611-623 [PMID: 17016496 DOI: 10.1038/sj.bjp.0706923]
37. Ishikawa TO, Oshima M, Herschman HR. Co x-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis 2011; 32: 417-426 [PMID: 21156970 DOI: 10.1093/carcin/bgq268.]
38. Park JM, Kanaoka Y , Eguchi N, Aritake K, Grujic S, Materi AM, Buslon VS, Tippin BL, Kwong AM, Salido E, French SW, Urade Y, Lin HJ. Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Res 2007; 67: 881-889 [PMID: 17283118 DOI: 10.1158/0008-5472. CAN-05-3767]
39. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, L u S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-betainduced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 2004; 101: 17468-17473 [PMID: 15574495 DOI: 10.1073/pnas.0406142101]
40. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, Byrom D, Riera A, Rossell D, Mangues R, Massagué J, Sancho E, Batlle E. Dependency of colorectal cancer on a TGF-?-driven program in stromal cells for metastasis initiation. Cancer Cell 2012; 22: 571-584 [PMID: 23153532 DOI: 10.1016/j.ccr.2012.08.013]
41. Algra AM, Rothwell PM. Effects of regular aspirin on longterm cancer incidence and metastasis: a systematic comparison of evidence from obser vational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527 [PMID: 22440112 DOI: 10.1016/S1470-2045(12)70112-2]
42. Rothwell P M, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 174 1-1750 [PMID: 20970847 DOI: 10.1016/S0140-6736(10)61543-7]
43. Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or lowdose aspirin use: old question new insights. World J Gastroenterol 2014; 20: 9439-9450 [PMID: 25071338 DOI: 10.3748/wjg.v20. i28.9439]
44. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, Logan RF, Rothwell PM, Schrör K, Baron JA. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 2012; 5: 164-178 [PMID: 22084361 DOI: 10.1158/1940-6207.capr-11-0391]
45. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucc i EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst 2015; 107: 345 [PMID: 25432409 DOI: 10.1093/jnci/dju345]
46. Ajuebor MN, Singh A, W allace JL. Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G238-G244 [PMID: 10898767 DOI: 10.1016/S0016-5085(0 0)85328-7]
47. Iwanaga K,Nakamura T,Maeda S,Aritake K,Hori M,Urade Y,Ozaki H,Murata T. Mast cell-derived prostaglandin D2 inhibits colitis and colitis-Associated colon cancer in mice Cancer Res 2014 74 3011-3019 PMID: 24879565 DOI: 10.1158/0008-5472. CAN-13-2792]
48. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomark ers Prev 1999; 8: 467-483 [PMID: 10350444]
49. Schewe T, Halangk W, Hiebsch C, Rapoport SM. A lipoxygenase in rabbit reticulocytes which attacks phospholipids and intact mitochondria. FEBS Le tt 1975; 60: 149-152 [PMID: 6318 DOI: 10.1016/0014-5793(75)80439-X]
50. Belkner J, Wiesner R, K ühn H, Lankin VZ. The oxygenation of cholesterol esters by the reticulocyte lipoxygenase. FEBS Lett 1991; 279: 110-114 [PMID: 1899834 DOI: 10.1016/0014-5793(91 )80263-3]
51. Rå dmark O, Samuelsson B. 5-Lipoxygenase: mechanisms of regulation. J Lipid Res 2009; 50 Suppl: S40-S45 [PMID: 18987389 DOI: 10.1194/jlr.R800062-JLR200]
52. Savari S, Vinnakota K, Zhang Y, Sjölander A. Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer. World J Gast roenterol 2014; 20: 968-977 [PMID: 24574769 DOI: 10.3748/wjg.v20.i4.968]
53. Rå dmark O, Werz O, Steinhi lber D, Samuels son B. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta 2015; 1851: 331-339 [PMID: 25152163 DOI: 10.1016/j.bbalip.2014.08.012]
54. Peters-Golden M. Molecular mechanisms of leukotriene synthesis: the changing paradigm. Clin Exp Allergy 1998; 28: 1059-1065 [PMID: 9761008 DOI: 10.1046/j.1365-2222.1998.00333.x]
55. Sharma JN, Mohammed LA. The role of leukotrienes in the pathophysiology of inflammatory diso rders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology 2006; 14: 10-16 [PMID: 16835707 DOI: 10.1007/s10787-006-1496-6]
56. Brock TG, Peters-Golden M. Activation and regulation of cellular eicosanoid biosynthesis. ScientificWorldJournal 2007; 7: 1273-1284 [PMID: 17767350 DOI: 10.1100/tsw.2007.180]
57. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA, Talamonti MS, Bell RH, Adrian TA. Overexpression of 5-lipoxygenase in colon polyps and cancer and t he effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 2008; 14: 6525-6530 [PMID: 18927292 DOI: 10.1158/1078-0432.CCR-07-4631]
58. Cheon EC, Khazaie K, Khan MW, S trouch MJ, Krantz SB, Phillips J, Blatner NR, Hix LM, Zhang M, Dennis KL, Salabat MR, Heiferman M, Grippo PJ, Munshi HG, Gounaris E, Bentrem DJ. Mast cell 5-lipoxygenase activity promotes intestinal pol yposis in APCDelta468 mice. Cancer Res 2011; 71: 1627-1636 [PMID: 21216893 DOI: 10.1158/0008-5472.CAN-10-1923]
59. Gounaris E, Heiferman MJ, Heiferman JR, Shrivastav M, Vitello D, Blatner NR, Knab LM, Phillips JD, Cheon EC, Grippo PJ, Khazaie K, Munshi HG, Bentrem DJ. Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic infla mmation. PLoS One 2015; 10: e0121402 [PMID: 25747113 DOI: 10.1371/journal. pone.0121402]
60. Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, Yasuno M, Enomoto M, Sugiha ra K. Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006; 12: 6355-6360 [PMID: 17072961 DOI: 10.3748/wjg.v12.i39.6355]
61. Klampfl T, Bogner E, Bednar W, Mager L, Massudom D, Kalny I, Heinzle C, Berger W, Stättner S, Karner J, Klimpfinger M, Fürstenberger G, Krieg P, Marian B. Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in colorectal cancer cells. Exp Cell Res 2012; 318: 768-778 [PMID: 22237009 DOI: 10.1016/j.yexcr.2011.12.017]
62. Prasad VV, Kolli P, Moganti D. Association of a functional polymorphism (Gln261Arg) in 12-lipoxygenase with breast cancer. Exp Ther Med 2011; 2: 317-323 [PMID: 22977504 DOI: 10.3892/etm.2011.209]
63. Prasad VV, Padma K. Non-synonymous polymorphism (Gln261Arg) of 12-lipoxygenase in colorectal and thyroid cancers. Fam Cancer 2012; 11: 615-621 [PMID: 22864639 DOI: 10.1007/s10689-012-9559-x]
64. Shan D, Shen K, Zhu J, Feng M, Wu Y, Wan C, Shen Y, Xu L. The polymorphism (Gln261Arg) of 12-lipoxygenase and cancer risk: a meta-Analysis. Int J Clin Exp Med 2015; 8: 488-495 [PMID: 25785021]
65. de Carvalho DD, Sadok A, Bourgarel-Rey V, Gattacceca F, P enel C, Lehmann M, Kovacic H. Nox1 downstream of 12-lipoxygenase controls cell proliferation but not cell spreading of colon cancer cells. Int J Cancer 2008; 122: 1757-1764 [PMID: 18076063 DOI: 10.1002/ijc.23300]
66. Kuhn H, Walther M, Kuban RJ. Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat 2002; 68-69: 263-290 [PMID: 12432923 DOI: 10.1016/s0090-6980(02)00035-7]
67. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippma n SM. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 2005; 65: 11486-11492 [PMID: 16357157 DOI: 10.1158/0008-5472.CAN-05-2180]
68. Moussalli MJ,Wu Y,Zuo X,Yang XL,Wistuba II,Raso MG,Morris JS,Bowser JL,Minna JD,Lotan R,Shureiqi I. Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to te rminal cell differentiation evasion Cancer Prev Res (Phila) 2011 4 1961-1972 PMID: 21881028 DOI: 10.1158/1940-6207.CAPR-10-0280]
69. Zuo X, Morris JS, Broaddus R, Shureiqi I. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene 2009; 28: 1496-1505 [PMID: 19198625 DOI: 10.1038/onc.2008.494]
70. Liu C, Xu D, Sjöberg J, Forsell P, Björkholm M, Claesson HE. Transcriptional regulation of 15-lipoxygenase expression by promoter methylation. Exp Cell Res 2004; 297: 61-67 [PMID: 15194425 DOI: 10.1016/j.yexcr.2004.02.014]
71. Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J 2008; 22: 1981-1992 [PMID: 18198215 DOI: 10.1096/fj.07-098301]
72. Shankaranarayanan P, Chaitidis P, Kühn H, Nigam S. Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for tran scriptional activation of the 15-lipoxygenase-1 gene. J Biol Chem 2001; 276: 42753-42760 [PMID: 11509556 DOI: 10.1074/jbc.M102626200]
73. Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, Wang Y, Parker-Thornburg J, Morris JS, Broaddus RR, Fischer SM, Shureiqi I. Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigen esis in mice. J Natl Cancer Inst 2012; 104: 709-716 [PMID: 22472308 DOI: 10.1093/jnci/djs187]
74. Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SM. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res (Phila) 2010; 3: 829-838 [PMID: 20570882 DOI: 10.1158/1940-6207. CAPR-09-0110]
75. Cimen I, Astarci E, Banerjee S. 15-lipoxygenase-1 exerts its tumor suppressive role by inhibiting nuclear factor-kappa B via activation of PPAR gamma. J Cell Biochem 2011; 112: 2490-2501 [PMID: 21544861 DOI: 10.1002/jcb.23174]
76. Hoesel B, Schmid JA. The complexity of NF-?B signaling in inflammation and cancer. Mol Cancer 2013; 12: 86 [PMID: 23915189 DOI: 10.1186/1476-4598-12-86]
77. Mangino MJ, Brounts L, Harms B, Heise C. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat 2006; 79: 84-92 [PMID: 16516812 DOI: 10.1016/j.prostaglandins. 2005.10.004]
78. Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH, Chan UP, Spelsberg TC. 15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferatoractivated receptor gamma-dependent pathway. Int J Cancer 2003; 107: 837-843 [PMID: 14566836 DOI: 10.1002/ijc.11447]
79. Eberhart CE, Coffey RJ, Radhika A, Giardi ello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188 [PMID: 7926468]
80. Tsu jii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501 [PMID: 8521479 DOI: 10.1016/0092-8674(95)90127-2]
81. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362-366 [PMID: 944341 8]
82. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276: 18075-18081 [PMID: 11278548 DOI: 10.1074 /jbc.M009689200]
83. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibitio n of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809 [PMID: 8945508 DOI: 10.1016/S0092-8674(00)81988-1]
84. Rigau J, Piqué JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952-954 [PMID: 1659272 DOI: 10.7326/00 03-4819-115-12-952]
85. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266 [PMID: 11854387 DOI: 10.1093/jnc i/94.4.252]
86. Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, Aaronson SA, Lee SW. P53-mediated induction of Cox-2 counteracts p53-or genotoxic stress-induced apoptosis. EMBO J 2002; 21: 5635-5644 [PMID: 12411481 DOI: 10.1093/emboj/cdf591]
87. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 20 00; 290: 989-992 [PMID: 11062132 DOI: 10.1126/science.290.5493.989]
88. Greenhough A, Wallam CA, Hicks DJ, Moorghen M, Williams AC, Paraskeva C. The proapoptotic BH3-only protein Bim is downre gulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. Oncogene 2010; 29: 3398-3410 [PMID: 20348947 DOI: 10.1038/onc.2010.94]
89. Kawa mori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003; 24: 985-990 [PMID: 12771044 DOI: 10.1093/carcin/bgg033]
90. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11: 2063-2073 [PMID: 15756033 DOI: 10.1158/1078-0432. CCR-04-1070]
91. Pai R, Soreghan B, Szabo IL , Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289-293 [PMID: 11875501 DOI: 10.1038/nm0302-289]
92. Limasale YD, Tezcaner A, Ö zen C, Keskin D, Banerjee S. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. Int J Pharm 2015; 479: 364-373 [PMID: 25595386 DOI: 10.1016/j.ijpharm.2015.01.016]
93. Roberts HR, Smartt HJ, Greenhough A, Moore AE, Williams AC, Paraskeva C. Colon tumour cells increase PGE(2) by regulating C OX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis 2011; 32: 1741-1747 [PMID: 21926111 DOI: 10.1093/carcin/bgr210]
94. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-Axin-beta-catenin signaling axis. Science 2005; 310: 1504-1510 [PMID: 16293724 DOI: 10.1126/science.1116221]
95. Cherukuri DP, Chen XB, Goulet AC, Young RN, Han Y, Heimark RL, Regan JW, Meuillet E, Nelson MA. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction a nd cell proliferation in HCA-7 colon cancer cells. Exp Cell Res 2007; 313: 2969-2979 [PMID: 17631291 DOI: 10.1016/j.yexcr.2007.06.004]
96. Park SW, Kim HS, Choi MS, Jeong WJ, Heo DS, Kim KH, Sung MW. The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells. J Pharmacol Exp Ther 2011; 336: 516-523 [PMID: 21062968 DOI: 10.1124/jpet.110.173278 ]
97. Chen GG, Lee JF, Wang SH, Chan UP, Ip PC, Lau WY. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Lif e Sci 2002; 70: 2631-2646 [PMID: 12269390 DOI: 10.1016/S0024-3205(02)01510-2]
98. Lin MS, Chen WC, Bai X, Wang YD. Activation of peroxisome proliferator-Activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J Dig Dis 2007; 8: 82-88 [PMID: 17532820 DOI: 10.1111/j.1443-9573.2007.00290.x]
99. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gam ma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-664 [PMID: 11950812 DOI: 10.1136/gut.50.5.658]
100. Koyama M, Izutani Y, Goda AE, Matsui TA, Horinaka M, To mosugi M, Fujiwara J, Nakamura Y, Wakada M, Yogosawa S, Sowa Y, Sakai T. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin Cancer Res 2010; 16: 2 320-2332 [PMID: 20371690 DOI: 10.1158/1078-0432.CCR-09-2301]
101. Shin SW, Seo CY, Han H, Han JY, Jeong JS, Kwak JY, Park JI. 15d-PGJ2 induces apoptosis by reactive oxygen speciesmediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res 2009; 15: 5414-5425 [PMID: 19690198 DOI: 10.1158/1078-0432. CCR-08-3101]
102. Wasil ewicz MP, Koodziej B, Boju?ko T, Kaczmarczyk M, Sulzyc-Bielicka V, Bielicki D, Ciepiela K. Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis. Int J Colorectal Dis 2010; 25: 1079-1085 [PMID: 20549218 DOI: 10.1007/s00384-010-0980-z]
103. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. Blockade of leukotriene B4 signaling pathway induces apoptosis and supp resses cell proliferation in colon cancer. J Pharmacol Sci 2007; 103: 24-32 [PMID: 17220595 DOI: 10.1254/jphs.FP0060651]
104. Ohd JF, Wikström K, Sjölander A. Leukotrienes induce cellsurvival signaling in intestinal epithelial cells. Gastroenterology 2000; 119: 1007-1018 [PMID: 11040187 DOI: 10.1053/gast.2000.18141]
105. Ohd JF, Nielsen CK, Campbell J, Landberg G, Löfberg H, Sjölander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003; 124: 57-70 [PMID: 12512030 DOI: 10.1053/gast.2003.50011]
106. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17: 1986-1995 [PMID: 14597668 DOI: 10.1096/fj.03-0053rev]
107. Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenase-Activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 1997; 185: 1065-1075 [PMID: 9091580 DOI: 10.1084/jem.185.6.1065]
108. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB. Protection from pulmonary fibrosis in leukotrien edeficient mice. Am J Respir Crit Care Med 2002; 165: 229-235 [PMID: 11790660 DOI: 10.1164/ajrccm.165.2.2104050]
109. Gavett SH, Madison SL, Chulada PC, Scarborough PE, Qu W, Boyle JE, Tiano HF, Lee CA, Langenbach R, Roggli VL, Zeldin DC. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 1999; 104: 721-732 [PMID: 10491407 DOI: 10.1172/jci6890]
110. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS, Chen X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and cele coxib. Clin Cancer Res 2005; 11: 2089-2096 [PMID: 15756036 DOI: 10.1158/1078-0432.CCR-04-1684]
111. Tavolari S,Bonafé M,Marini M,Ferreri C,Bartolini G,Brighenti E,Manara S,Tomasi V,Laufer S,Guarnieri T. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade Car cinogenesis 2008 29 371-380 PMID: 18033773 DOI: 10.1093/carcin/bgm265]
112. Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, Schiavone N, Messerini L, Vannacci A, Capaccioli S, Perna F, Lulli M, Fabbroni V, Perigli G, Bechi P, Masini E. Inhibit ion of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 2006; 5: 2716-2726 [PMID: 17121918 DOI: 10.1158/1535-7163.MCT-06-0318]
113. Bhattacharya S, Mathew G, Jayne DG, Pelengaris S, Khan M. 15-lipoxygenase-1 in colorectal cancer: a review. Tumour Biol 2009; 30: 185-199 [PMID: 19752603 DOI: 10.1159/000236864]
114. Kami tani H, Geller M, Eling T. Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 1998; 273: 21569-21577 [PMID: 9705287 DOI: 10.1074/jbc.273.34 .21569]
115. Yoshinaga M, Buchanan FG, DuBois RN. 15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK 1/2 signaling in colon carcinoma cells. Prostaglandins Other Lipid Mediat 2004; 73: 1 11-122 [PMID: 15165036 DOI: 10.1016/j.prostaglandins.200 4.01.001]
116. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 1999; 20: 1985-1995 [PMID: 10506115 DOI: 10.1093/carcin/20.10.1985]
117. Cimen I, Tunç ay S, Banerjee S. 15-Lipoxygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines HCT-116 and HT-29. Cancer Sci 2009; 100: 2283-2291 [PMID: 19775287 DOI: 10.1111/j.1349-7006.2009.01313.x]
118. Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H, Kuniyasu H. Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology 2007; 51: 520-527 [PMID: 17711445 DOI: 10.1111/j.1365-2559.2007.02799. x]
119. Zuo X, Shureiqi I. Eicosanoid profiling in colon cancer: emergence of a pattern. Prostaglandins Other Lipid Mediat 2013; 104-105: 139-143 [PMID: 22960430 DOI: 10.1016/j.prostaglandins.2012.08 .004]
120. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759 [PMID: 16175180 DOI: 10.1038/nri1703]
121. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxiso me proliferator-Activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2011; 2: 236-240 [PMID: 22247890 DOI: 10.4103/2231-4040.90879]
122. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999; 3: 799-804 [PMID: 103 94368 DOI: 10.1016/S1097-2765(01)80012-5]
123. Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J, Green E, Hofmann W, Taguchi H, Koeffler HP. Mutational analysis of th e peroxisome proliferator-Activated receptor gamma gene in human malignancies. Cancer Res 2001; 61: 5307-5310 [PMID: 11431375]
124. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M. Ligands for peroxisome proliferatoractivated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61: 2424-2428 [PMID: 112891 09]
125. Chen ZY, Tseng CC. 15-deoxy-Delta12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-Activated receptor gamma by activating the mitogen-Activated protein kinas e kinase/extracellular signalregulated kinase signal transduction pathway in HT-29 colon cancer cells. Mol Pharmacol 2005; 68: 1203-1213 [PMID: 16077033 DOI: 10.1124/mol.105.014944]
126. Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, Menegatti E, Daniela B, Minelli R, Giglioni B, Dianzani MU, Ferretti C, Barrera G. PPARgamma ligands inhibit telomerase activity and hTERT expressio n through modulation of the Myc/Mad/Max network in colon cancer cells. J Cell Mol Med 2010; 14: 1347-1357 [PMID: 19912441 DOI: 10.1111/j.1582-4934.2009.00966.x]
127. Nagy L, Tontonoz P, Alv arez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-240 [PMID: 9568715 DOI: 10.1016/S0092-8674(00)81574-3]
128. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 2006; 25: 1225-1241 [PMID: 16288226 DOI: 10.1038/sj.onc.1209160]
129. Sasaki T, Fujii K, Yoshida K, Shimura H, Sasahira T, Ohmori H, Kuniyasu H. Peritoneal metastasis inhibition by linoleic acid with ac tivation of PPARgamma in human gastrointestinal cancer cells. Virchows Arch 2006; 448: 422-427 [PMID: 16362414 DOI: 10.1007/s00428-005-0110-4]
130. Natarajan C, Bright JJ. Peroxisome proli ferator-Activated receptorgamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002; 3: 59-70 [PMID: 11960303 DOI: 10.1038/sj.gene.63638 32]
131. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55: 1341-1349 [PMID: 16905700 DOI: 10.1136/gut.2006.093484]
132. Shureiqi I,Jiang W,Zuo X,Wu Y,Stimmel JB,Leesnitzer LM,Morris JS,Fan HZ Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 2003 100 9968-9973 PMID: 12909723 DOI: 10.1073/pnas.1631086100]
133. Zhong H, Wang R, Kelavkar U, Wang CY, Simons J. Enzyme 15-lipoxygenase 1 promotes hypoxia-inducible factor 1? turnover and reduces vascular endothelial growth factor expression: implications for angiogenesis. Cancer Med 2014; 3: 514-525 [PMID: 24668884 DOI: 10.1002/cam4.227]
134. Mao F, Xu M, Zuo X, Yu J, Xu W, Moussalli MJ, Elias E, Li HS, Watowich SS, Shureiqi I. 15-Lipoxygenase-1 suppression of colitis-Associated colon cancer through inhibition of the IL-6/STAT3 signal ing pathway. FASEB J 2015; 29: 2359-2370 [PMID: 25713055 DOI: 10.1096/fj.14-264515]
135. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferatoractivated receptor-delta accelerates intestinal adenoma growth. Nat Med 2004; 10: 245-247 [PMID: 14758356 DOI: 10.1038/nm993]
136. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-Activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000; 97: 13275-13280 [PMID: 11087869 DOI: 10.1073/pn as.97.24.13275]
137. Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Expression of PPARdelta in multista ge carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer 2006; 95: 889-895 [PMID: 16969348 DOI: 10.1038/sj.bjc.6603343]
138. Wu KK, Liou JY. Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPARdelta-& gt; 14-3-3epsilon pathway. Methods Mol Biol 2009; 512: 295-307 [PMID: 19347284 DOI: 10.1007/978-1-60327-530-9-16]
139. Cutler NS, G raves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, Morrow JD, Coffey RJ. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 2003; 63: 1748-1751 [PMID: 12702555]
140. Jeong E, Koo JE, Yeon SH, Kwak MK, Hwang DH, Lee JY. PPAR? deficiency disrupts hypoxia-mediated tumorigenic potential of colon cancer cells. Mol Carcinog 2014; 53: 926-937 [PMID: 24610641 DOI: 10.1002/mc.22144]
141. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005; 5: 199-209 [PMID: 15738983 DOI: 10.1038/nrc1569]
142. Lurje G, Zhang W, Lenz HJ. Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer 2007; 6: 683-690 [PMID: 18039421 DOI: 10.3816/CCC.2007.n.037]
143. Dubois RN. Role of inflammation and inflammatory mediators in colorectal cancer. Trans Am Clin Climatol Assoc 2014; 125: 358-72; discussion 372-3 [PMID: 25125751]
144. Usman MW, Luo F, Cheng H, Zhao JJ, Liu P. Chemopreventive effects of aspirin at a glance. Biochim Biophys Acta 2015; 1855: 254-263 [PMID: 25842298 DOI: 10.1016/j.bbcan.2015.03.007]
145. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601 [PMID: 22440947 DOI: 10.1016/S0140-6736(12)60209-8]
146. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The CO X-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-386 [PMID: 19136477 DOI: 10.1093/carcin/bgp014]
147. Cianchi F, Cortesini C, Bechi P, FantappiéO, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E. Upregulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121: 1339-1347 [PMID: 11729113 DOI: 10.1053/gast.2001.29691]
148. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 2010; 295: 7-16 [PMID: 20381235 DOI: 10.1016/j.canlet.2010.03.015]
149. Radinsky R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 1995; 14: 323-338 [PMID: 8821093 DOI: 10.1007/BF00690601]
150. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Pro staglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 35451-35457 [PMID: 12824187 DOI: 10.1074/jbc.M302474200]
151. Buchanan F G, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-Arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 2006; 103: 1492-1497 [PMID: 16432186 DOI: 10.1073/ pnas.0510562103]
152. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 2003; 17: 1640-1647 [PMID: 12958170 DOI: 10.1096/fj.02-1011com]
153. Fujino H, Toyomura K, Chen XB, Regan JW, Murayama T. Prostaglandin E? regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochem Pharmacol 2011; 81: 379-387 [PMID: 21070749 DOI: 10.1016/j.bcp.2010.11.001]
154. Hsu HH, Hu WS, Lin YM, Kuo WW, Chen LM, Chen WK, Hwang JM, Tsai FJ, Liu CJ, Huang CY. JNK suppression is essential for 17?-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions an d cell migration in human LoVo colon cancer cells. J Biomed Sci 2011; 18: 61 [PMID: 21859479 DOI: 10.1186/1423-0127-18-61]
155. Daneker GW, Lund SA, Caughman SW, Staley CA, Wood WC. Anti-metastatic prostacyclins inhibit the adhesion of colon carcinoma to endothelial cells by blocking E-selectin expression. Clin Exp Metastasis 1996; 14: 230-238 [PMID: 8674277 DOI: 10.1007/BF00053896]
156. Cathcart MC, Lysaght J, Pidgeon GP. Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer Metastasis Rev 2011; 30: 363-385 [PMID : 22134655 DOI: 10.1007/s10555-011-9324-x]
157. Koontongkaew S, Monthanapisut P, Saensuk T. Inhibition of arachidonic acid metabolism decreases tumor cell invasion and matrix metalloproteinase expression. Prostagland ins Other Lipid Mediat 2010; 93: 100-108 [PMID: 20654727 DOI: 10.1016/j.prost aglandins.2010.07.002]
158. Hennig R, Kehl T, Noor S, Ding XZ, Rao SM, Bergmann F, Fürstenberger G, Büchler MW, Friess H, Krieg P, Adrian TE. 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 2007; 9: 917-926 [PMID: 18030360 DOI: 10 .1593/neo.07565]
159. Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E, Xu W, Shureiqi I. 15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1? expression in human colon cancer cells. Cance r Med 2014; 3: 472-484 [PMID: 24634093 DOI: 10.1002/cam4.222]
160. Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer 2011; 2: 1085-1096 [PMID: 22866200 DOI: 10.1177/1947601911432334]
161. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life 2001; 52: 61-66 [PMID: 11795595 DOI: 10.1080/15216540252774784]
162. Brown NS, Streeter EH, Jones A, Harris AL, Bicknell R. Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br J Cancer 2005; 92: 1696-1701 [PMID: 15841086 DOI: 10.1038/sj.bjc.6602522]
163. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon c ancer cells. J Biol Chem 2002; 277: 38205-38211 [PMID: 12149254 DOI: 10.1074/jbc.M203781200]
164. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of v ascular endothelial growth factor. J Biol Chem 1996; 271: 736-741 [PMID: 8557680 DOI: 10.1074/jbc.271.2.736]
165. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003; 63: 2330-2334 [PMID: 12727858]
166. Jurek D, Udilova N, Jozkowicz A, Nohl H, Mari an B, Schulte-Hermann R. Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells. FASEB J 2005; 19: 97-99 [PMID: 15522906 DOI: 10.1096/fj.04-2111fje]
167. Ko HM, Seo KH, Han SJ, Ahn KY, Choi IH, Koh GY, Lee HK, Ra MS, Im SY. Nuclear factor kappaB dependency of plateletactivating factor-induced angiogenesis. Cancer Res 2002; 62: 1809-1814 [PMID: 11912159]
168. Mezentsev A, Seta F, Dunn MW, Ono N, Falck JR, Laniado-Schwartzman M. Eicosanoid regulation of vascular endothelial growth factor expression and angiogenesis in microvessel endothelial cells. J Biol Chem 2002; 277: 18670-18676 [PMID: 11901160 DOI: 10.1074/jbc.M201143200]
169. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon ca ncer cells. Cell 1998; 93: 705-716 [PMID: 9630216 DOI: 10.1016/S0092-8674(00)81433-6]
170. Ochs AM, Wong L, Kakani V, Neerukonda S, Gorske J, Rao A, Riggs M, Ward H, Keville L. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer 2004; 4: 262-267 [PMID: 15555209 DOI: 10.3816/CCC.2004.n.025]
171. Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006; 9: 6-8 [PMID: 16413466 DOI: 10.1016/j.ccr.2005.12.029]
172. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005; 280: 26565-26572 [PMID: 15899904 DOI: 10.1074/jbc.M413056200]
173. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 200 1; 7: 1048-1051 [PMID: 11533709 DOI: 10.1038/nm0901-1048]
174. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN. CXCL1 induced by pro staglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006; 203: 941-951 [PMID: 16567391 DOI: 10.1084/jem.20052124]
175. Kim SH,Park YY,Kim SW,Lee JS,Wang D,DuBois RN ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression Cancer Res 2011 71 7010-7020 PMID: 21937683 DOI: 10.1158/0008-5472. CAN-11-1262]
176. Dormond O, Bezzi M, Mariotti A, Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-Activation, and spreading through cAMP/PKAdependent signaling. J Biol Chem 2002; 277: 4 5838-45846 [PMID: 12237321 DOI: 10.1074/jbc.M209213200]
177. Salcedo R, Zhang X, Young HA, Michael N, Wasserman K, Ma WH, Martins-Green M, Murphy WJ, Oppenheim JJ. Angiogenic effects of prostag landin E2 are mediated by upregulation of CXCR4 on human microvascular endothelial cells. Blood 2003; 102: 1966-1977 [PMID: 12791666 DOI: 10.1182/blood-2002-11-3400]
178. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999; 59: 4574-4577 [PMID: 10493510]
179. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, Nukiwa T. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cance r Res 2002; 62: 63-66 [PMID: 11782360]
180. Abdel-Majid RM, Marshall JS. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immu nol 2004; 172: 1227-1236 [PMID: 14707101 DOI: 10.4049/jimmunol.172.2.1227]
181. Nakayama T, Mutsuga N, Yao L, Tosato G. Prostaglandin E2 promotes degranulation-independent release of MCP-1 from ma st cells. J Leukoc Biol 2006; 79: 95-104 [PMID: 16275896 DOI: 10.1189/jlb.0405226]
182. Gentile LB, Piva B, Diaz BL. Hypertonic stress induces VEGF production in human colon cancer cell line Caco-2: inhibitory role of autocrine PGE?. PLoS One 2011; 6: e25193 [PMID: 21980393 DOI: 10.1371/journal.p one.0025193]
183. Grau R, Iñiguez MA, Fresno M. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carc inoma cells: evidence for a redoxsensitive peroxisome proliferator-Activated receptor-gammaindependent mechanism. Cancer Res 2004; 64: 5162-5171 [PMID: 15289320]
184. Ye YN, Liu ES, Shin VY, Wu WK , Luo JC, Cho CH. Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J Pharmacol Exp Ther 2004; 308: 66-72 [PMID: 14569062 DOI: 10.1124/jpe t.103.058321]
185. Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-Associated colonic tumorigenesis by cigarette sm oking. Toxicology 2004; 203: 179-188 [PMID: 15363593 DOI: 10.1016/j.tox.2004.06.004]
186. Ye YN, Wu WK, Shin VY, Cho CH. A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Eur J Pharmacol 2005; 519: 52-57 [PMID: 16125168 DOI: 10.1016/j.ejphar.2005.07.009]
187. Savari S, Liu M, Zhang Y, Sime W, Sjölander A. CysLT(1)R antagoni sts inhibit tumor growth in a xenograft model of colon cancer. PLoS One 2013; 8: e73466 [PMID: 24039952 DOI: 10.1371/journal.pone.0073466]
188. Rosengren S, Olofsson AM, von Andrian UH, Lundgren-Akerlund E, Arfors KE. Leukotriene B4-induced neutrophil-mediated endothelial leakage in vitro and in vivo. J Appl Physiol (1985) 1991; 71: 1322-1330 [PMID: 1661722]
189. Steiner DR, Gonzalez NC, Wood JG. Leukotriene B(4) promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J Appl Physiol (1985) 2001; 91: 1160-1167 [PMID: 11509511]
190. Kim GY, Lee JW, Cho SH, Seo JM, Kim JH. Role of the low-Affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler Thromb Vasc Biol 2009; 29: 915-920 [PMID: 19286633 DOI: 10.1161/ATVBAHA.109.185793]
191. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Leukotrienes C4 and D4 promote angiogenesis via a receptormediated interaction. Eur J Pharmacol 1994; 258: 151-154 [PMID: 7523148 DOI: 10.1016/001 4-2999(94)90068-X]
192. Kanaoka Y, Maekawa A, Penrose JF, Austen KF, Lam BK. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotr iene C4 synthase. J Biol Chem 2001; 276: 22608-22613 [PMID: 11319240 DOI: 10.1074/jbc.M103562200]
193. Cimen I. The mechanism of antitumorigenic effect of 15-Lipoxygenase-1 in colorectal cancer. PhD Thes is, Department of Biological Sciences: Middle East Technical University, 2012. Available from: URL: http://library.metu.edu.tr/search~S15?/a{u00C7}imen/ac~aimen/1,9,10,B/l856~b2013263&FF=ac~aimen ismail&1,1,1,0
194. Serhan CN, Chiang N, Dalli J, Levy BD. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol 2015; 7: a016311 [PMID: 25359497 DOI: 10.1101/cshperspect.a016311]
195. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 163-177 [PMID: 16125378 DOI: 10.1016/j.plefa.2005.05.003]
196. Norris PC,Gosselin D,Reichart D,Glass CK,Dennis EA. Phospholipase A2 regulates eicosanoid class switching during inflammasome activation Proc Natl Acad Sci USA 2014 111 12746-12751 PMID: 25139986 DOI: 10.1073/pnas.1404372111]
197. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF, Williams IR, Neish AS, Madara JL. Lipoxin a4 analogs attenuate indu ction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 2002; 168: 5260-5267 [PMID: 11994483 DOI: 10.4049/jimmunol.168.10.5260]
198. Gronert K, Gewirtz A, Madara JL, Serhan CN. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med 1998; 187: 1285-1294 [PMID: 9547339 DOI: 10.1084/jem.187.8.1285]
199. Kure I, Nishiumi S, Nishitani Y, Tanoue T, Ishida T, Mizuno M, Fujita T, Kutsumi H, Arita M, Azu ma T, Yoshida M. Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factorkappaB activation. J Pharmacol Exp Ther 2010; 332: 541-548 [PMID: 19846590 DOI: 10.1124/jpet.109.159046]
200. Vong L, Ferraz JG, Dufton N, Panaccione R, Beck PL, Sherman PM, Perretti M, Wallace JL. Up-regulation of Annexin-A1 and lipoxin A(4) in indivi duals with ulcerative colitis may promote mucosal homeostasis. PLoS One 2012; 7: e39244 [PMID: 22723974 DOI: 10.1371/journal.pone.0039244]
201. Prescott D, McKay DM. Aspirin-triggered lipoxin enhances macro phage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol 2011; 301: G487-G497 [PMID: 21659618 DOI: 10.1152/ajpgi.00042.2011]
202. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol 2015; 27: 200-215 [PMID: 25857211 DOI: 10.1016/j.smim.2015.03.004]
203. Campbell EL, Louis NA, Tomassetti SE, Canny GO, Arita M, Serhan CN, Colgan SP. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolut ion. FASEB J 2007; 21: 3162-3170 [PMID: 17496159 DOI: 10.1096/fj.07-8473com]
204. Campbell EL, MacManus CF, Kominsky DJ, Keely S, Glover LE, Bowers BE, Scully M, Bruyninckx WJ, Colgan SP. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci USA 2010; 107: 14298-14303 [PMID: 20660763 DOI: 10.1073/pnas.0914730107]
205. Hull MA, Sandell AC, Montgomery AA, Logan RF, Clifford GM, Rees CJ, Loadman PM, Whitham D. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. Trials 2013; 14: 237 [PMID: 23895505 DOI: 10.1186/1745-6215-14-23 7]
206. Marcon R, Bento AF, Dutra RC, Bicca MA, Leite DF, Calixto JB. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of col itis. J Immunol 2013; 191: 4288-4298 [PMID: 24038091 DOI: 10.4049/jimmunol.1202743]
207. Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-mod erate asthma: results of a systematic review with meta-Analysis. Arch Dis Child 2010; 95: 365-370 [PMID: 19946008 DOI: 10.1136/adc.2009.169177]